Overview

Angiotensin 1-7 (Ang-(1-7)) is a naturally occurring heptapeptide that functions as a counter-regulatory hormone within the renin-angiotensin system (RAS). Unlike angiotensin II, which promotes vasoconstriction and inflammation, Ang-(1-7) acts through the Mas receptor to produce beneficial cardiovascular, metabolic, and anti-aging effects.

Research suggests this peptide may serve as a protective factor against hypertension, metabolic syndrome, cardiovascular aging, and inflammatory conditions. Studies indicate it works by promoting vasodilation, reducing inflammation, improving insulin sensitivity, and supporting endothelial function.

The peptide has gained attention for its potential therapeutic applications in cardiovascular disease, diabetes, and age-related vascular dysfunction, though human clinical data remains limited.

Mechanism of Action

Angiotensin 1-7 exerts its effects primarily through binding to the Mas receptor, a G-protein coupled receptor that mediates protective cardiovascular and metabolic responses. Key mechanisms include:

Cardiovascular Protection:

• Activates endothelial nitric oxide synthase (eNOS) to promote vasodilation
• Reduces vascular smooth muscle cell proliferation
• Inhibits inflammatory cytokine production (TNF-α, IL-6)
• Enhances endothelial function and vascular compliance

Metabolic Effects:

• Improves insulin sensitivity through enhanced glucose uptake
• Reduces adipose tissue inflammation
• Modulates adipokine production (increased adiponectin)
• Supports healthy lipid metabolism

Anti-Aging Properties:

• Protects against vascular senescence
• Reduces oxidative stress through antioxidant enzyme activation
• Maintains telomere length in endothelial cells
• Counteracts age-related vascular dysfunction

Research Summary

Research on Angiotensin 1-7 spans over two decades with 10+ significant papers published and 5 clinical trials registered. The evidence strongly supports its cardioprotective and metabolic benefits in preclinical models.

Key Studies

Cardiovascular Protection (2014, Hypertension) This comprehensive review established Ang-(1-7) as a key protective arm of the RAS, demonstrating vasodilatory, anti-inflammatory, and cardioprotective effects in multiple animal models of hypertension and heart disease.

Metabolic Syndrome Prevention (2014, Peptides) Research demonstrated that Ang-(1-7) administration prevented diet-induced obesity, improved glucose tolerance, and reduced inflammatory markers in rodent models. The study showed significant improvements in insulin sensitivity and lipid profiles.

Anti-Cancer Activity (2014, Current Medicinal Chemistry) Studies indicated potential anti-proliferative effects against various cancer cell lines, though the clinical significance remains unclear. The peptide appeared to inhibit angiogenesis and tumor growth in preclinical models.

Inflammation and Adipokines (2019, Metabolism) Clinical research showed associations between plasma Ang-(1-7) levels and improved metabolic markers in humans. Higher endogenous levels correlated with better insulin sensitivity and lower inflammatory markers.

Vascular Anti-Aging (2022, Peptides) Recent research demonstrated protective effects against vascular aging, including preservation of endothelial function, reduced arterial stiffness, and improved vascular reactivity in aged animal models.

Clinical Trials

Five clinical trials are currently investigating Ang-(1-7) or related compounds:

• Salt sensitivity studies in young adults (NCT04026776)
• Cardiovascular protection trials (NCT06746753)
• Liver transplantation applications (NCT04901169)

Dosage Guidelines

Human dosing protocols for Angiotensin 1-7 are not yet established, as most research has been conducted in preclinical models. Animal studies typically use doses ranging from 0.1-1.0 mg/kg, but direct translation to humans requires clinical validation.

Research Dosing Context:

• Animal studies: 0.1-1.0 mg/kg daily
• Duration: 2-12 weeks in studies
• Route: Subcutaneous or intravenous
• Monitoring: Blood pressure, metabolic markers

Safety Profile

Safety data for Angiotensin 1-7 comes primarily from animal studies, with limited human exposure data. The peptide appears generally well-tolerated in preclinical research.

Reported Effects in Research:

• Mild hypotension (dose-dependent)
• Generally well-tolerated in animal studies
• No significant adverse events in limited human exposure

Contraindications:

• Pre-existing hypotension or low blood pressure
• Concurrent use of multiple blood pressure medications
• Pregnancy and breastfeeding (unknown effects)
• Pediatric use (no safety data)

Monitoring Recommendations:

• Blood pressure (risk of hypotension)
• Cardiovascular parameters
• Metabolic markers (glucose, lipids)
• Kidney function

Regulatory Note: Not approved for human use in any jurisdiction. Available for research purposes only.

Stacking

Due to limited human data, stacking protocols for Angiotensin 1-7 are largely theoretical. Potential combinations should consider cardiovascular effects and drug interactions.

Theoretically Compatible:

• BPC-157: May complement cardiovascular protective effects
• Metabolic peptides: Could enhance insulin sensitivity benefits
• Cardiovascular support compounds: Require careful blood pressure monitoring

Avoid Combining With:

• Multiple blood pressure medications without medical supervision
• Other vasodilatory compounds (risk of excessive hypotension)
• Uncharacterized research compounds

Monitoring Requirements: Any stacking approach would require comprehensive cardiovascular monitoring, including blood pressure, heart rate, and metabolic parameters. Given the experimental nature of this peptide, conservative approaches are recommended.

References

1. Angiotensin-(1-7). (2014). Hypertension (Dallas, Tex. : 1979). DOI PubMed
2. Angiotensin 1-7: a peptide for preventing and treating metabolic syndrome. (2014). Peptides. DOI PubMed
3. Angiotensin-(1-7): a peptide hormone with anti-cancer activity. (2014). Current medicinal chemistry. DOI PubMed
4. Angiotensin-(1-7), Adipokines and Inflammation. (2019). Metabolism: clinical and experimental. DOI PubMed
5. Angiotensin-(1-7), a protective peptide against vascular aging. (2022). Peptides. DOI PubMed
6. Angiotensin (1-7) peptide replacement therapy with plasma transfusion in COVID-19. (2022). Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. DOI PubMed
7. Angiotensin-(1-7): an update. (2000). Regulatory peptides. DOI PubMed
8. Therapeutic uses for Angiotensin-(1-7). (2016). Expert opinion on therapeutic patents. DOI PubMed
9. Angiotensin-(1-7): Translational Avenues in Cardiovascular Control. (2019). American journal of hypertension. DOI PubMed
10. Angiotensin-(1-7) mediated calcium signalling by MAS. (2023). Peptides. DOI PubMed